Evidence supporting the use of: Iodine
For the health condition: Radiation Sickness

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 4

Iodine, specifically in the form of potassium iodide (KI), is scientifically validated for use in certain scenarios of radiation exposure, but with important limitations. The primary rationale is not to treat radiation sickness in general, but to protect the thyroid gland from radioactive iodine isotopes, most notably iodine-131, which may be released during nuclear accidents or radiological events. When taken shortly before or soon after exposure to radioactive iodine, potassium iodide saturates the thyroid with stable (non-radioactive) iodine, thereby reducing uptake of the harmful isotope. This significantly lowers the risk of thyroid cancer and other thyroid-related conditions, especially in children, who are most susceptible.

The evidence for this use is robust. The World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), and U.S. Food and Drug Administration (FDA) all recommend potassium iodide tablets for populations at risk of radioactive iodine exposure. Historical episodes, such as the Chernobyl nuclear disaster, have demonstrated that populations who received potassium iodide had lower rates of thyroid cancer compared to those who did not. However, it is crucial to note that potassium iodide does not protect against other forms of radiation or treat the broader spectrum of radiation sickness. It is only effective for blocking the thyroid’s uptake of radioactive iodine and must be administered at the correct time relative to exposure.

More about iodine
More about Radiation Sickness